Drugs & TargetsFree MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program October 08, 2021Vol.47 No.37
Drugs & TargetsFree NEXT Oncology expands phase I program with VCS partnership October 08, 2021Vol.47 No.37
Drugs & Targets FDA grants 510(k) clearance to Koya Medical’s lymphedema treatment October 01, 2021Vol.47 No.36
Drugs & Targets Novilase breast therapy granted FDA breakthrough designation October 01, 2021Vol.47 No.36
Drugs & Targets Acelarin gets FDA Fast Track designation for treatment of biliary tract cancer October 01, 2021Vol.47 No.36
Drugs & Targets Libtayo sBLA granted FDA priority review in 2L recurrent or metastatic cervical cancer October 01, 2021Vol.47 No.36
Drugs & Targets FDA issues draft guidance on assessing electronic health records and medical claims data October 01, 2021Vol.47 No.36
Drugs & Targets MD Anderson and BostonGene announce collaboration to advance personalized cancer diagnostics and treatments October 01, 2021Vol.47 No.36
Drugs & Targets Jakafi receives FDA approval for treatment of chronic GVHD September 24, 2021Vol.47 No.35
Drugs & Targets Cabometyx receives FDA approval for patients with previously treated radioactive iodine-refractory differentiated thyroid cancer September 24, 2021Vol.47 No.35
